You searched for "presentation"
Neuroendocrine bladder tumour
A 75-year-old male with a history of prostate adenocarcinoma (T3b/T4 N1 M1b, Gleason 4+3) on Zoladex® and enzalutamide, presented with visible haematuria. His prostate specific antigen (PSA) had decreased from 43.6ug/L in December 2022 to 0.02ug/L. He also had a...Peyronie’s disease: a review and update
Peyronie’s disease (PD) describes an acquired disease of the penis, which is characterised by a number of signs and symptoms. These include penile pain, curvature, palpable plaques, wasting or narrowing of the penile shaft, a hinge deformity and potentially catastrophic...In conversation with Sarika Nalagatla
We were delighted to catch up with Sarika Nalagatla, new Chair of the BAUS Section of Trainees (BSoT) about her life as a trainee urologist and plans for the association. Can you tell us a little bit about what led...Neurourology
Case 1 What are the urological indications for use of this medication? What is the mechanism of action when used in the bladder? What is the average duration of action? What are the contraindications to the use of this medication?...HIV / AIDS – implications for the urologist
“It’s no fun to have HIV even though it’s viewed as a chronic, controllable disease. It means being wedded to the health system.” - Philip Berger, Associate Professor in the Department of Family and Community Medicine, Toronto, Canada; and leading...EAU (European Association of Urology) Talent Incubator Programme: Policy & Innovation
The randomised controlled trial (RCT) will remain one of the most important methods for medical advancements. A solid framework, an extensive network and financial resources are key factors in the success of a trial. In this module of the Talent Incubator Programme, we will address the practical side of conducting research and trials with support from policy experts, industry representatives and patient advocatesThe Bladder & Bowel UK Symposium North West 2025
The Bladder & Bowel UK Symposium provides healthcare professionals with an excellent opportunity to receive relevant education from national speakers. The event includes a brand new programme of inspirational lectures, multi-disciplinary discussions and case studies to influence best practices, together with an extensive exhibition including company representatives and charitable services.Focal therapy for prostate cancer – ready for prime time?
The current therapeutic ratio for radical therapy in many men with localised prostate cancer is not ideal. For a significant side-effect profile, there seems to be a small survival benefit over a 10-15 year period. A strategy that might balance...Clear cell urothelial carcinoma: a highly aggressive morphological variant in the bladder and upper urinary tract
Clear cell urothelial carcinoma (CCUC) is a rare morphological variant of transitional cell carcinoma (TCC). It can occur anywhere along the urothelial tract and is characterised histologically by high grade carcinoma with an abundance of clear, glycogen-rich cytoplasm [1]. Alternative...A ‘survival guide’ to an ST3 year in urology
Following success in national selection, it soon dawns on the successful candidate that entry into higher surgical training (HST) requires more than a little clinical knowledge. The role requires administrative and organisational skills not hitherto called upon. This additional skill...In conversation with Ian Pearce
We were delighted to catch up with our old friend, Ian Pearce, former Editor of Urology News and new President of BAUS. Can you tell us a little bit about what led you into the field of urology and the...
